Covidien Quits Renal Denervation Race; Others Stick It Out, For Now
This article was originally published in The Gray Sheet
Executive Summary
A Covidien executive said in an interview that the firm’s decision to halt development of its OneShot renal denervation system was made prior to Medtronic’s recent announcement that its Symplicity device missed its endpoint. Covidien cites slower-than-expected development of the renal denervation market.